HIV - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols HTT and TPR	Name 1 huntingtin	Name2 translocated promoter region, nuclear basket protein	Pathway 1 Regulation of MECP2 expression and activity	Pathway 2 ISG15 antiviral mechanism Transport of the SLBP independent Mature mRNA Transport of the SLBP Dependant Mature mRNA Transport of Mature mRNA Derived from an Intronless Transcript Transport of Mature mRNA derived from an Intron-Containing Transcript Rev-mediated nuclear export of HIV RNA Transport of Ribonucleoproteins into the Host Nucleus NS1 Mediated Effects on Host Pathways Viral Messenger RNA Synthesis NEP/NS2 Interacts with the Cellular Export Machinery Regulation of Glucokinase by Glucokinase Regulatory Protein Nuclear import of Rev protein Vpr-mediated nuclear import of PICs IPs transport between nucleus and cytosol IP3 and IP4 transport between cytosol and nucleus IP6 and IP7 transport between cytosol and nucleus snRNP Assembly SUMOylation of DNA damage response and repair proteins SUMOylation of ubiquitinylation proteins Nuclear Pore Complex (NPC) Disassembly Regulation of HSF1-mediated heat shock response SUMOylation of SUMOylation proteins SUMOylation of chromatin organization proteins SUMOylation of RNA binding proteins SUMOylation of DNA replication proteins SUMOylation of DNA replication proteins Transcriptional regulation by small RNAs Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) tRNA processing in the nucleus HCMV Early Events HCMV Late Events SARS-CoV-2 activates/modulates innate and adaptive immune responses Signaling by ALK fusions and activated point mutants	Drugs 1 Copper	Drugs 2	Diseases 1 Huntington's disease (HD)	Diseases 2 Thyroid cancer
Novel Novel	Symbols IGF1R and KL	Name 1 insulin like growth factor 1 receptor	Name2 klotho	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2
Novel Novel	Symbols IGF1R and DOK5	Name 1 insulin like growth factor 1 receptor	Name2 docking protein 5	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2 RET signaling	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2
Novel Novel	Symbols BYSL and L3MBTL3	Name 1 bystin like	Name2 L3MBTL histone methyl-lysine binding protein 3	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols BYSL and KATNAL1	Name 1 bystin like	Name2 katanin catalytic subunit A1 like 1	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols BYSL and LHX3	Name 1 bystin like	Name2 LIM homeobox 3	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2 Regulation of expression of SLITs and ROBOs	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
Novel Novel	Symbols CBL and SORBS2	Name 1 Cbl proto-oncogene	Name2 sorbin and SH3 domain containing 2	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2
Novel Novel	Symbols CBL and LRIG1	Name 1 Cbl proto-oncogene	Name2 leucine rich repeats and immunoglobulin like domains 1	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2 Signaling by EGFR Negative regulation of MET activity Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin	Drugs 1	Drugs 2	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2
Novel Novel	Symbols KRT18 and NEFL	Name 1 keratin 18	Name2 neurofilament light chain	Pathway 1 Keratinization Formation of the cornified envelope Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Pathway 2 Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
Novel Novel	Symbols LMNA and SLC38A7	Name 1 lamin A/C	Name2 solute carrier family 38 member 7	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel Novel	Symbols LMNA and TM4SF20	Name 1 lamin A/C	Name2 transmembrane 4 L six family member 20	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel Novel	Symbols LMNA and NALCN	Name 1 lamin A/C	Name2 sodium leak channel, non-selective	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2 Stimuli-sensing channels	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel Novel	Symbols LMNA and SFT2D2	Name 1 lamin A/C	Name2 SFT2 domain containing 2	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel Novel	Symbols XRCC6 and RNF146	Name 1 X-ray repair cross complementing 6	Name2 ring finger protein 146	Pathway 1 2-LTR circle formation Cytosolic sensors of pathogen-associated DNA IRF3-mediated induction of type I IFN Nonhomologous End-Joining (NHEJ) Neutrophil degranulation	Pathway 2 TCF dependent signaling in response to WNT Degradation of AXIN Ub-specific processing proteases Regulation of PTEN stability and activity	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols MBD1 and NELL1	Name 1 methyl-CpG binding domain protein 1	Name2 neural EGFL like 1	Pathway 1 SUMOylation of transcription cofactors	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols MBD1 and HUNK	Name 1 methyl-CpG binding domain protein 1	Name2 hormonally up-regulated Neu-associated kinase	Pathway 1 SUMOylation of transcription cofactors	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols MCM7 and MCM8	Name 1 minichromosome maintenance complex component 7	Name2 minichromosome maintenance 8 homologous recombination repair factor	Pathway 1 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state	Pathway 2 E2F-enabled inhibition of pre-replication complex formation Activation of ATR in response to replication stress Unwinding of DNA CDC6 association with the ORC:origin complex Orc1 removal from chromatin Activation of the pre-replicative complex	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols MCM7 and ELOC	Name 1 minichromosome maintenance complex component 7	Name2 elongin C	Pathway 1 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state	Pathway 2 Formation of RNA Pol II elongation complex Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha Formation of HIV elongation complex in the absence of HIV Tat Formation of HIV-1 elongation complex containing HIV-1 Tat Pausing and recovery of Tat-mediated HIV elongation Tat-mediated HIV elongation arrest and recovery Tat-mediated elongation of the HIV-1 transcript HIV elongation arrest and recovery Pausing and recovery of HIV elongation Vif-mediated degradation of APOBEC3G RNA Polymerase II Pre-transcription Events TP53 Regulates Transcription of DNA Repair Genes RNA Polymerase II Transcription Elongation Neddylation Regulation of expression of SLITs and ROBOs Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling Antigen processing: Ubiquitination & Proteasome degradation Evasion by RSV of host interferon responses Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols MCM7 and C8orf34	Name 1 minichromosome maintenance complex component 7	Name2 chromosome 8 open reading frame 34	Pathway 1 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FHL2 and BARX2	Name 1 four and a half LIM domains 2	Name2 BARX homeobox 2	Pathway 1 PPARA activates gene expression	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols HTT and TPR	Name 1 huntingtin	Name2 translocated promoter region, nuclear basket protein	Pathway 1 Regulation of MECP2 expression and activity	Pathway 2 ISG15 antiviral mechanism Transport of the SLBP independent Mature mRNA Transport of the SLBP Dependant Mature mRNA Transport of Mature mRNA Derived from an Intronless Transcript Transport of Mature mRNA derived from an Intron-Containing Transcript Rev-mediated nuclear export of HIV RNA Transport of Ribonucleoproteins into the Host Nucleus NS1 Mediated Effects on Host Pathways Viral Messenger RNA Synthesis NEP/NS2 Interacts with the Cellular Export Machinery Regulation of Glucokinase by Glucokinase Regulatory Protein Nuclear import of Rev protein Vpr-mediated nuclear import of PICs IPs transport between nucleus and cytosol IP3 and IP4 transport between cytosol and nucleus IP6 and IP7 transport between cytosol and nucleus snRNP Assembly SUMOylation of DNA damage response and repair proteins SUMOylation of ubiquitinylation proteins Nuclear Pore Complex (NPC) Disassembly Regulation of HSF1-mediated heat shock response SUMOylation of SUMOylation proteins SUMOylation of chromatin organization proteins SUMOylation of RNA binding proteins SUMOylation of DNA replication proteins SUMOylation of DNA replication proteins Transcriptional regulation by small RNAs Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) tRNA processing in the nucleus HCMV Early Events HCMV Late Events SARS-CoV-2 activates/modulates innate and adaptive immune responses Signaling by ALK fusions and activated point mutants	Drugs 1 Copper	Drugs 2	Diseases 1 Huntington's disease (HD)	Diseases 2 Thyroid cancer
Novel	Symbols IGF1R and KL	Name 1 insulin like growth factor 1 receptor	Name2 klotho	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2
Novel	Symbols IGF1R and DOK5	Name 1 insulin like growth factor 1 receptor	Name2 docking protein 5	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2 RET signaling	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2
Novel	Symbols BYSL and L3MBTL3	Name 1 bystin like	Name2 L3MBTL histone methyl-lysine binding protein 3	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols BYSL and KATNAL1	Name 1 bystin like	Name2 katanin catalytic subunit A1 like 1	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols BYSL and LHX3	Name 1 bystin like	Name2 LIM homeobox 3	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2 Regulation of expression of SLITs and ROBOs	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
Novel	Symbols CBL and SORBS2	Name 1 Cbl proto-oncogene	Name2 sorbin and SH3 domain containing 2	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2
Novel	Symbols CBL and LRIG1	Name 1 Cbl proto-oncogene	Name2 leucine rich repeats and immunoglobulin like domains 1	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2 Signaling by EGFR Negative regulation of MET activity Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin	Drugs 1	Drugs 2	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2
Novel	Symbols KRT18 and NEFL	Name 1 keratin 18	Name2 neurofilament light chain	Pathway 1 Keratinization Formation of the cornified envelope Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Pathway 2 Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
Novel	Symbols LMNA and SLC38A7	Name 1 lamin A/C	Name2 solute carrier family 38 member 7	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel	Symbols LMNA and TM4SF20	Name 1 lamin A/C	Name2 transmembrane 4 L six family member 20	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel	Symbols LMNA and NALCN	Name 1 lamin A/C	Name2 sodium leak channel, non-selective	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2 Stimuli-sensing channels	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel	Symbols LMNA and SFT2D2	Name 1 lamin A/C	Name2 SFT2 domain containing 2	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel	Symbols XRCC6 and RNF146	Name 1 X-ray repair cross complementing 6	Name2 ring finger protein 146	Pathway 1 2-LTR circle formation Cytosolic sensors of pathogen-associated DNA IRF3-mediated induction of type I IFN Nonhomologous End-Joining (NHEJ) Neutrophil degranulation	Pathway 2 TCF dependent signaling in response to WNT Degradation of AXIN Ub-specific processing proteases Regulation of PTEN stability and activity	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols MBD1 and NELL1	Name 1 methyl-CpG binding domain protein 1	Name2 neural EGFL like 1	Pathway 1 SUMOylation of transcription cofactors	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols MBD1 and HUNK	Name 1 methyl-CpG binding domain protein 1	Name2 hormonally up-regulated Neu-associated kinase	Pathway 1 SUMOylation of transcription cofactors	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols MCM7 and MCM8	Name 1 minichromosome maintenance complex component 7	Name2 minichromosome maintenance 8 homologous recombination repair factor	Pathway 1 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state	Pathway 2 E2F-enabled inhibition of pre-replication complex formation Activation of ATR in response to replication stress Unwinding of DNA CDC6 association with the ORC:origin complex Orc1 removal from chromatin Activation of the pre-replicative complex	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols MCM7 and ELOC	Name 1 minichromosome maintenance complex component 7	Name2 elongin C	Pathway 1 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state	Pathway 2 Formation of RNA Pol II elongation complex Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha Formation of HIV elongation complex in the absence of HIV Tat Formation of HIV-1 elongation complex containing HIV-1 Tat Pausing and recovery of Tat-mediated HIV elongation Tat-mediated HIV elongation arrest and recovery Tat-mediated elongation of the HIV-1 transcript HIV elongation arrest and recovery Pausing and recovery of HIV elongation Vif-mediated degradation of APOBEC3G RNA Polymerase II Pre-transcription Events TP53 Regulates Transcription of DNA Repair Genes RNA Polymerase II Transcription Elongation Neddylation Regulation of expression of SLITs and ROBOs Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling Antigen processing: Ubiquitination & Proteasome degradation Evasion by RSV of host interferon responses Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols MCM7 and C8orf34	Name 1 minichromosome maintenance complex component 7	Name2 chromosome 8 open reading frame 34	Pathway 1 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FHL2 and BARX2	Name 1 four and a half LIM domains 2	Name2 BARX homeobox 2	Pathway 1 PPARA activates gene expression	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2

Page 13 out of 31 pages

Search Results : HIV